



# Professional Development Breakouts

**OHDSI Community Call**  
**June 15, 2021 • 11 am ET**



# Upcoming OHDSI Community Calls

Date	Topic
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management, Open-Source Software Development, Statistical Methods
June 22	Community Brainstorm: Health Equity Research
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance)
July 6	Meet & Greet New OHDSI Collaborators
July 13	Focus Topic: PROTEUS
July 20	Workgroup Updates: Early-Stage Researchers, Women of OHDSI, Latin America, Education
July 27	Visualization Challenge



# Upcoming OHDSI Community Calls

Date	Topic
June 15	Professional Development Breakouts: Clinical Epidemiology, Information/Data Management, Open-Source Software Development, Statistical Methods
June 22	Community Brainstorm: Health Equity Research
June 29	Focus Topic: EUMEAUS (Evaluating Use of Methods for Adverse Event Under Surveillance)
July 6	Meet & Greet New OHDSI Collaborators
July 13	Focus Topic: PROTEUS
July 20	Workgroup Updates: Early-Stage Researchers, Women of OHDSI, Latin America, Education
July 27	Visualization Challenge



# Three Stages of The Journey

**Where Have We Been?**

**Where Are We Now?**

**Where Are We Going?**





# OHDSI Shoutouts!

Congratulations to **Xintong Li, Anna Ostropolets, Rupa Makadia, Azza Shoaibi, Gowtham Rao, Anthony Sena, Eugenia Martinez-Hernandez, Antonella Delmestri, Katia Verhamme, Peter Rijnbeek, Talita Duarte-Salles, Marc Suchard, Patrick Ryan, George Hripcsak, Daniel Prieto-Alhambra** for the study “Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study” that was posted yesterday in *The BMJ*.

thebmj

covid-19

Research

Education

News & Views

Campaigns

Jobs

Research » Special paper

Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study

BMJ 2021 ; 373 doi: <https://doi.org/10.1136/bmj.n1435> (Published 14 June 2021)

Cite this as: BMJ 2021;373:n1435

Incidence rate per 100 000 person years (95% prediction interval)							
Outcomes by sex	1-5 years	6-17 years	18-34 years	35-54 years	55-64 years	65-74 years	≥85 years
Non-haemorrhagic stroke							
Female	4.0 (2.9 to 5.4)	4.0 (3.0 to 5.4)	18.4 (14.6 to 23.0)	83.1 (61.7 to 112.0)	217.0 (172.0 to 272.0)	413.0 (317.0 to 529.0)	874.0 (677.0 to 1121.0)
Male	6.0 (4.5 to 8.0)	5.0 (3.5 to 7.0)	17.0 (13.0 to 22.0)	119.0 (91.0 to 157.0)	379.0 (294.0 to 494.0)	612.0 (455.0 to 799.0)	1063.0 (802.0 to 1404.0)
Acute myocardial infarction							
Female	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.5)	6.0 (4.5 to 8.0)	14.0 (10.0 to 19.0)	171.0 (130.0 to 222.0)	312.0 (236.0 to 409.0)	417.0 (314.0 to 550.0)
Male	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.5)	16.0 (12.0 to 21.0)	46.0 (35.0 to 61.0)	63.0 (47.0 to 84.0)	93.0 (70.0 to 124.0)	114.0 (85.0 to 151.0)
Deep vein thrombosis							
Female	12.0 (9.0 to 16.0)	18.0 (14.0 to 24.0)	140.0 (106.0 to 184.0)	306.0 (227.0 to 409.0)	428.0 (324.0 to 562.0)	683.0 (507.0 to 909.0)	1206.0 (877.0 to 1635.0)
Male	14.0 (10.0 to 19.0)	14.0 (10.0 to 19.0)	80.0 (58.0 to 109.0)	272.0 (198.0 to 366.0)	499.0 (366.0 to 662.0)	695.0 (500.0 to 940.0)	1003.0 (728.0 to 1378.0)
Haemorrhagic stroke							
Female	7.0 (5.0 to 9.0)	5.0 (3.0 to 7.0)	13.0 (9.0 to 18.0)	36.0 (27.0 to 47.0)	77.0 (55.0 to 104.0)	124.0 (89.0 to 169.0)	412.0 (285.0 to 539.0)
Male	8.0 (6.0 to 10.0)	8.0 (6.0 to 10.0)	19.0 (14.0 to 25.0)	31.0 (22.0 to 42.0)	115.0 (83.0 to 157.0)	179.0 (127.0 to 240.0)	312.0 (217.0 to 407.0)
Pulmonary embolism							
Female	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.5)	38.0 (28.0 to 50.0)	81.0 (57.0 to 110.0)	125.0 (90.0 to 170.0)	217.0 (157.0 to 297.0)	427.0 (314.0 to 550.0)
Male	1.0 (0.7 to 1.5)	1.0 (0.7 to 1.5)	20.0 (15.0 to 27.0)	80.0 (58.0 to 109.0)	171.0 (127.0 to 222.0)	256.0 (186.0 to 336.0)	349.0 (254.0 to 464.0)
Appendicitis							
Female	32.0 (24.0 to 42.0)	154.0 (105.0 to 203.0)	134.0 (98.0 to 180.0)	85.0 (62.0 to 114.0)	66.0 (48.0 to 90.0)	53.0 (38.0 to 72.0)	40.0 (29.0 to 54.0)
Male	36.0 (27.0 to 48.0)	154.0 (105.0 to 203.0)	144.0 (105.0 to 193.0)	88.0 (64.0 to 118.0)	65.0 (47.0 to 89.0)	57.0 (41.0 to 78.0)	45.0 (32.0 to 61.0)
Bell's palsy							
Female	15.0 (10.0 to 21.0)	25.0 (18.0 to 34.0)	44.0 (32.0 to 59.0)	61.0 (45.0 to 81.0)	76.0 (56.0 to 101.0)	86.0 (63.0 to 114.0)	101.0 (74.0 to 134.0)
Male	15.0 (10.0 to 21.0)	21.0 (15.0 to 29.0)	43.0 (32.0 to 58.0)	68.0 (50.0 to 91.0)	86.0 (63.0 to 114.0)	94.0 (69.0 to 124.0)	102.0 (75.0 to 134.0)
Anaphylaxis							
Female	49.0 (36.0 to 65.0)	50.0 (36.0 to 68.0)	39.0 (28.0 to 53.0)	34.0 (24.0 to 47.0)	35.0 (25.0 to 48.0)	29.0 (21.0 to 39.0)	23.0 (16.0 to 32.0)
Male	74.0 (54.0 to 100.0)	56.0 (40.0 to 77.0)	29.0 (21.0 to 39.0)	24.0 (17.0 to 33.0)	25.0 (18.0 to 34.0)	24.0 (17.0 to 33.0)	18.0 (13.0 to 25.0)
Immune thrombocytopenia							
Female	12.0 (8.0 to 18.0)	9.0 (6.0 to 13.0)	14.0 (9.0 to 21.0)	15.0 (10.0 to 22.0)	18.0 (12.0 to 27.0)	25.0 (17.0 to 36.0)	36.0 (25.0 to 51.0)
Male	17.0 (12.0 to 24.0)	8.0 (5.0 to 13.0)	12.0 (8.0 to 18.0)	10.0 (7.0 to 14.0)	19.0 (13.0 to 28.0)	30.0 (21.0 to 42.0)	41.0 (29.0 to 57.0)
Myocarditis or pericarditis							
Female	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	16.0 (10.0 to 25.0)	22.0 (15.0 to 32.0)	31.0 (21.0 to 44.0)	35.0 (24.0 to 49.0)	39.0 (27.0 to 54.0)
Male	2.0 (1.0 to 3.0)	11.0 (7.0 to 16.0)	37.0 (24.0 to 55.0)	37.0 (24.0 to 55.0)	45.0 (30.0 to 66.0)	49.0 (33.0 to 68.0)	54.0 (37.0 to 74.0)
Disseminated intravascular coagulation							
Female	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	4.0 (2.0 to 7.0)	5.0 (3.0 to 8.0)	10.0 (6.0 to 16.0)	14.0 (9.0 to 21.0)	19.0 (13.0 to 28.0)
Male	3.0 (1.0 to 7.0)	2.0 (1.0 to 3.0)	4.0 (2.0 to 7.0)	5.0 (3.0 to 8.0)	12.0 (7.0 to 19.0)	17.0 (11.0 to 25.0)	23.0 (15.0 to 34.0)
Encephalomyelitis							
Female	5.0 (3.0 to 8.0)	5.0 (3.0 to 8.0)	5.0 (3.0 to 8.0)	6.0 (4.0 to 9.0)	9.0 (6.0 to 13.0)	11.0 (7.0 to 16.0)	12.0 (8.0 to 18.0)
Male	4.0 (2.0 to 7.0)	5.0 (3.0 to 8.0)	5.0 (3.0 to 8.0)	7.0 (5.0 to 10.0)	12.0 (8.0 to 18.0)	14.0 (9.0 to 21.0)	16.0 (11.0 to 23.0)
Narcolepsy							
Female	1.0 (0.5 to 1.5)	7.0 (4.0 to 11.0)	15.0 (10.0 to 21.0)	11.0 (7.0 to 16.0)	9.0 (6.0 to 13.0)	8.0 (5.0 to 11.0)	9.0 (6.0 to 13.0)
Male	1.0 (0.5 to 1.5)	6.0 (4.0 to 9.0)	13.0 (9.0 to 18.0)	10.0 (7.0 to 14.0)	11.0 (7.0 to 16.0)	10.0 (7.0 to 14.0)	10.0 (7.0 to 14.0)
Guillain-Barré syndrome							
Female	1.0 (0.5 to 1.5)	1.0 (0.5 to 1.5)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	5.0 (3.0 to 8.0)	6.0 (4.0 to 9.0)	7.0 (5.0 to 10.0)
Male	2.0 (1.0 to 3.0)	1.0 (0.5 to 1.5)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	5.0 (3.0 to 8.0)	6.0 (4.0 to 9.0)	7.0 (5.0 to 10.0)
Transverse myelitis							
Female	1.0 (0.5 to 1.5)	1.0 (0.5 to 1.5)	3.0 (2.0 to 4.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)
Male	1.0 (0.5 to 1.5)	1.0 (0.5 to 1.5)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)	4.0 (3.0 to 5.0)
Council of International Organizations of Medical Sciences frequency classification							
Very rare (<1/10,000)	Rare (<1/1,000 to ≥1/10,000)		Uncommon (<1/100 to ≥1/1,000)		Common (<1/10 to ≥1/100)		Very common (≥1/10)



# OHDSI Shoutouts!



Who We Are ▾ OHDSI Updates & News ▾ Standards ▾ Software Tools ▾ OHDSI Studies ▾ Book of OHDSI ▾ Resources ▾ New To OHDSI? ▾

EHDI ▾ Academic ▾ Community News & Updates ▾ COVID-19 Research ▾ 2021 Global Symposium ▾ Events/Collaborations ▾ Collaborate in MStems ▾ Follow OHDSI ▾

Home ▸ COVID-19 Updates Page

## COVID-19 Updates Page

The Observational Health Data Sciences and Informatics (OHDSI) international community hosted a COVID-19 virtual study-a-thon March 26-29 to inform healthcare decision-making in response to the current global pandemic. That work served as the foundation for global community research into characterization, population-level effect estimation and patient-level prediction questions about the disease. Ongoing work continues in the OHDSI MStems environment; if you wish to join the OHDSI Teams environment, [please fill this form out](#). Once there, you can tell us [which working groups or studies](#) you would like to join.

## Published Studies

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, Alser O, Alshammari TM, Biedermann P, Banda JM, Burn E, Casajust P, Conover MM, Culhane AC, Davydov A, DuVall SL, Dymshyts D, Fernandez-Bertolin S, Flister K, Hardin J, Hester L, Hripscak G, Kaas-Hansen BS, Kent S, Khosla S, Kolovos S, Lambert CG, van der Lei J, Lynch KE, Makadia R, Margulis AV, Matheny ME, Mehta P, Morales DR, Morgan-Stewart H, Mosseveld M, Newby D, Nyberg F, Ostropolets A, Park RW, Prats-Urbe A, Rao GA, Reich C, Reps J, Rijnbeek P, Sathappan SMK, Schuemie M, Seager S, Sena AG, Shoaibi A, Spotnitz M, Suchard MA, Torre CO, Vizcaya D, Wen H, de Wilde M, Xie J, You SC, Zhang L, Zhuk O, Ryan P, Prieto-Alhambra D; OHDSI-COVID-19 consortium. [Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study](#). *Lancet Rheumatol*. 2020 Nov;2(11):e698-e711. doi: 10.1016/S2665-9913(20)30276-9. Epub 2020 Aug 21. PMID: 32864627; PMCID: PMC7442425. [\[OHDSI press release\]](#)

Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahao MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC, Davydov A, DeFalco FJ, Duarte-Salles T, DuVall S, Falconer T, Fernandez-Bertolin S, Gao W, Golozar A, Hardin J, Hripscak G, Huser V, Jeon H, Jing Y, Jung CY, Kaas-Hansen BS, Kaduk D, Kent S, Kim Y, Kolovos S, Lane JCE, Lee H, Lynch KE, Makadia R, Matheny ME, Mehta PP, Morales DR, Natarajan K, Nyberg F, Ostropolets A, Park RW, Park J, Posada JD, Prats-Urbe A, Rao G, Reich C, Rho Y, Rijnbeek P, Schilling LM, Schuemie M, Shah NH, Shoaibi A, Song S, Spotnitz M, Suchard MA, Swerdel JN, Vizcaya D, Volpe S, Wen H, Williams AE, Yimer BB, Zhang L, Zhuk O, Prieto-Alhambra D, Ryan P. [Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study](#). *Nat Commun*. 2020 Oct 6;11(1):5009. doi: 10.1038/s41467-020-18849-z. PMID: 33024121; PMCID: PMC7538555. [\[OHDSI press release\]](#)

Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernandez-Bertolin S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Urbe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripscak G, Suchard MA. [Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis](#). *Lancet Digit Health*. 2021 Feb;3(2):e98-e114. doi: 10.1016/S2589-7500(20)30289-2. Epub 2020 Dec 17. PMID: 33342753; PMCID: PMC7834915. [\[OHDSI press release\]](#)

Tan EH, Sena AG, Prats-Urbe A, You SC, Ahmed WU, Kostka K, Reich C, Duvall SL, Lynch KE, Matheny ME, Duarte-Salles T, Bertolin SF, Hripscak G, Natarajan K, Falconer T, Spotnitz M, Ostropolets A, Blacketer C, Alshammari TM, Alghoul H, Alser O, Lane JCE, Dawoud DM, Shah K, Yang Y, Zhang L, Areia C, Golozar A, Recalde M, Casajust P, Jonnagaddala J, Subbian V, Vizcaya D, Lai LY, Nyberg F, Morales DR, Posada JD, Shah NH, Gong M, Vivekanantham A, Abend A, Minty EP, Suchard M, Rijnbeek P, Ryan PB, Prieto-Alhambra D. [Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis](#). *Rheumatology (Oxford)*. 2021 Mar 16;keab250. doi: 10.1093/rheumatology/keab250. PMID: 33269355; PMCID: PMC7709171.

Shoaibi A, Fortin S, Weinstein R, Berlin J, Ryan P. [Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients. The American Journal of Gastroenterology](#). 2021 Jan 28. doi: 10.14309/ajg.0000000000001153

Prats-Urbe A, Sena AG, Lai LY, Ahmed W, Alghoul H, Alser O, Alshammari TM, Areia C, Carter W, Casajust P, Dawoud D, Golozar A, Jonnagaddala J, Mehta P, Gong M, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Shah K, Shah NH, Schilling L, Subbian V, Vizcaya D, Zhang L, Zhang Y, Zhu H, Liu L, Cho J, You SC, Rijnbeek P, Hripscak G, Lane JCE, Burn E, Reich C, Suchard M, Duarte-Salles T, Kostka K, Ryan PB, Prieto-Alhambra D. [Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study](#). *BMJ*. 373 2021; doi:10.1136/bmj.n1038. [\[OHDSI press release\]](#)

Duarte-Salles T, Vizcaya D, Pistillo A, Casajust P, Sena AG, Lai LY, Prats-Urbe A, Ahmed W, Alshammari TM, Alghoul H, Alser O, Burn E, You SC, Areia C, Blacketer C, Duvall S, Falconer T, Carter W, Fernandez-Bertolin S, Fortin S, Golozar A, Gong M, Tan EH, Huser V, Ivell P, Morales DR, Nyberg F, Posada J, Recalde M, Roel E, Schilling L, Shah NH, Shah K, Suchard M, Zhang L, Zhang Y, Williams A, Reich C, Hripscak G, Rijnbeek P, Ryan PB, Kostka K, Prieto-Alhambra D. [30-day outcomes of children and adolescents with COVID-19: an international experience](#). *Pediatrics*. 2021; doi: 10.1542/peds.2020-042929. [\[OHDSI press release\]](#)

Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, Martinez-Hernandez E, Delmestri A, Verhamme K, Rijnbeek P, Duarte-Salles T, Suchard M, Ryan PB, Hripscak G, Prieto-Alhambra D. [Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study](#). *BMJ* 2021;373:n1435; doi: 10.1136/bmj.n1435. [\[OHDSI press release\]](#)

## Preprints

Prieto-Alhambra D, et al. [Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS](#). doi: 10.21203/rs.3.rs-279400/v1

Williams R, et al. [Seek COVER: Development and validation of a personalized risk calculator for COVID-19 outcomes in an international network](#). doi: 10.1101/2020.05.26.20112649

Recalde M, et al. [Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom](#). doi: 10.1101/2020.09.02.20185173

Lai L, et al. [Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis](#). doi: 10.1101/2020.10.13.20211821

Roel E, et al. [Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain](#). doi: 10.1101/2021.01.12.21249672



[www.ohdsi.org/covid-19-updates](http://www.ohdsi.org/covid-19-updates)





# OHDSI Shoutouts!



**Any shoutouts from the community? Please share and help promote and celebrate OHDSI work!**

Have a study published? Please send to [sachson@ohdsi.org](mailto:sachson@ohdsi.org) so we can share during this call and on our social channels.  
Let's work together to promote the collaborative work happening in OHDSI!





# Three Stages of The Journey

**Where Have We Been?**

**Where Are We Now?**

**Where Are We Going?**







# Upcoming Workgroup Calls



Date	Time (ET)	Meeting
Tuesday	1 pm	Common Data Model
Tuesday	3 pm	OMOP CDM Oncology – Genomic Subgroup
Wednesday	8 am	Vaccine Vocabulary
Wednesday	10 am	OMOP CDM Oncology — Development Subgroup
Wednesday	1 pm	Data Quality Dashboard
Thursday	12 pm	HADES
Thursday	1 pm	OMOP CDM Oncology — CDM/Vocabulary Subgroup
Friday	10 am	Education
Tuesday	9 am	OMOP CDM Oncology – Genomic Subgroup

[www.ohdsi.org/upcoming-working-group-calls](http://www.ohdsi.org/upcoming-working-group-calls)



# Next APAC Community Call – June 17

- Professor **Lei Liu** of Fudan University will provide a presentation on “Applying the OMOP CDM to Hepatobiliary Clinical Research Database at Zhongshan Hospital.”
- **Mui Van Zandt** will lead a discussion about collecting attitudinal information from the community to support planning and activities.

## OHDSI APAC - Our Asia-Pacific Community

OHDSI is a global, multi-stakeholder, interdisciplinary and open-science network that collaborates to bring out the value of health data through large-scale analytics. Our Asia-Pacific (APAC) community comprises six regional chapters (Australia, China, Japan, Singapore, South Korea, Taiwan) and has led important OHDSI initiatives around the world.

The [first OHDSI APAC Symposium](#) was held virtually Dec. 5-6, 2020, and it provided an opportunity for our Asia-Pacific collaborators (along with others around the world) to share research, provide community updates, collaborate in regional breakouts or network discussions, and have some OHDSI fun.



### Upcoming APAC Community Calls

Date	Topic
May 6	Collaborator Showcase Presentations
May 20	10-Minute Tutorials
June 3	Network Research
June 17	Welcome to OHDSI
July 1	OMOP Projects

[@OHDSI](#) [www.ohdsi.org](http://www.ohdsi.org) [#JoinTheJourney](#) [linkedin.com/company/ohdsi](https://linkedin.com/company/ohdsi)

The APAC community has its own group in the OHDSI MS Teams environment to promote greater collaboration on our collaborative efforts. It will also be the home of our bi-weekly APAC Community Calls, where we will provide updates, share research presentations, collaborate on topics of shared interest, and plenty more. How can you get involved? First, [request access to our MS Teams Environment](#), then request access to [our OHDSI APAC workgroup](#). You can also join the meetings [by using this direct link](#).

Our calls are scheduled on a bi-weekly basis, held every other Thursday/Wednesday depending on where you live. All calls are recorded, so if you miss one or want to share with a collaborator, check out the call recordings below.

- + June 3, 2021 - APAC Network Research
- + May 22, 2021 - 10-Minute Tutorials
- + May 8, 2021 - Collaborator Presentations
- + Apr. 22, 2021 - Regional Updates
- + Apr. 8, 2021 - OMOP Projects (Presentations by Yuan Lu and Namki Hong)



# Get Access To Different Teams/WGs/Chapters



**Welcome to OHDSI!**

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All our solutions are open-source.

OHDSI has established an international network

**2020 OHDSI Symposium**

Our 2020 OHDSI Global Symposium brought together a global research community for 18 hours of open science, international collaboration and community fun. The day included research presentations from community members, panels that brought together leaders from major healthcare organizations, as well as network sessions, the annual collaborator

4. Select the workgroups you want to join (you can refer to the WIKI for work group objectives [www.ohdsi.org/web/wiki/doku.php?id=projects:overview](http://www.ohdsi.org/web/wiki/doku.php?id=projects:overview))

- ☐ ATLAS
- ☐ Clinical Trials
- ☐ Common Data Model
- ☐ Data Quality Dashboard Development
- ☐ Early-stage Researchers
- ☐ Education Work Group
- ☐ Electronic Health Record (EHR) ETL
- ☐ Geographic Information System (GIS)
- ☐ HADES Health Analytics Data-to-Evidence Suite
- ☐ Latin America
- ☐ Medical Devices
- ☐ Natural Language Processing
- ☐ OHDSI APAC
- ☐ OHDSI APAC Steering Committee
- ☐ OHDSI Steering Committee
- ☐ Oncology
- ☐ Patient-Generated Health Data
- ☐ Pharmacovigilance Evidence Investigation

- ☐ Phenotype Development and Evaluation
- ☐ Population-Level Effect Estimation / Patient-Level Prediction
- ☐ Psychiatry
- ☐ Registry (formerly UK Biobank)
- ☐ Surgery and Perioperative Medicine
- ☐ Vaccine Vocabulary
- ☐ Women of OHDSI


5. Select the chapter(s) you want to join

- ☐ Australia
- ☐ China
- ☐ Europe
- ☐ Japan
- ☐ Korea
- ☐ Singapore
- ☐ Taiwan

6. Select the studies you want to join

- ☐ HERA-Health Equity Research Assessment
- ☐ PIONEER for Prostate Cancer (study-a-thon ended)
- ☐ SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)

# Get Access To Different Teams/WGs/Chapters



The screenshot shows the OHDSI website with the navigation menu at the top. The 'Collaborate in MStTeams' link is highlighted with a red circle. Below the menu, the '2020 OHDSI Symposium' banner is visible. The 'Join Work groups, Chapters, and Studies Registration' form is shown, with the 'Join Work groups, Ch...' link highlighted with a red circle. The form includes a required field for '1. First and Last Name'.

**Welcome to OHDSI!**

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced 'oh-dsee') program is a multi-stakeholder collaborative to bring out the value through large-scale analytics. All teams are open to all collaborators. Below please indicate which Team you would like to join and the OHDSI coordinating center team will grant access.

OHDSI has established

**OHDSI MStTeams Work groups, Chapters, and Studies Registration**

OHDSI is using MStTeams to further encourage active collaboration within the community. Within the OHDSI organization, there are separate teams for work groups, chapters, and studies, as well as OHDSI community activities (such as the OHDSI2020 Symposium). All teams are open to all collaborators. Below please indicate which Team you would like to join and the OHDSI coordinating center team will grant access.

\* Required

1. First and Last Name \*

Enter your answer

4. Select the workgroups you want to join (you can refer to the WIKI for work group objectives [www.ohdsi.org/web/wiki/doku.php?id=projects:overview](http://www.ohdsi.org/web/wiki/doku.php?id=projects:overview))

- ☐ ATLAS
- ☐ Clinical Trials
- ☐ Common Data Model
- ☐ Data Quality Dashboard Development
- ☐ Early-stage Researchers
- ☐ Education Work Group
- ☐ Electronic Health Record (EHR) ETL
- ☐ Geographic Information System (GIS)
- ☐ HADES Health Analytics Data-to-Evidence Suite
- ☐ Latin America
- ☐ Medical Devices
- ☐ Natural Language Processing
- ☐ OHDSI APAC
- ☐ OHDSI APAC Steering Committee
- ☐ OHDSI Steering Committee
- ☐ Oncology
- ☐ Patient-Generated Health Data
- ☐ Pharmacovigilance Evidence Investigation

- ☐ Phenotype Development and Evaluation
- ☐ Population-Level Effect Estimation / Patient-Level Prediction
- ☐ Psychiatry
- ☐ Registry (formerly UK Biobank)
- ☐ Surgery and Perioperative Medicine
- ☐ Vaccine Vocabulary
- ☐ Women of OHDSI

5. Select the chapter(s) you want to join

- ☐ Australia
- ☐ China
- ☐ Europe
- ☐ Japan
- ☐ Korea
- ☐ Singapore
- ☐ Taiwan

6. Select the studies you want to join

- ☐ HERA-Health Equity Research Assessment
- ☐ PIONEER for Prostate Cancer (study-a-thon ended)
- ☐ SCYLLA (SARS-Cov-2 Large-scale Longitudinal Analyses)



# CBER Seminar Series

The next edition of the CBER BEST Initiative Seminar Series will be **TOMORROW at 11 am ET. Bruce Fireman** (Kaiser Permanente) will present a talk on “Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines.” The seminar series is open to everybody. Get more information and register by using the link below.



Webinar Registration



Topic	CBER BEST Initiative Seminar Series - Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines
Description	<p>Methods for Monitoring the Safety and Effectiveness of COVID-19 vaccines</p> <p>We review statistical methods used in observational studies of the safety and effectiveness of COVID-19 vaccines. Topics include:</p> <ul style="list-style-type: none"><li>- How to compare recent vaccinees with concurrent comparators (unvaccinated or less recently vaccinated) and with comparators who are not concurrent (historical rates or self-controls) to make inferences about outcome rates that would be expected among vaccinees had they not been vaccinated.</li><li>- Methods for estimating risk ratios</li><li>- How to examine change in vaccine effectiveness (waning) or vaccine safety over time-since-vaccination</li><li>- Sequential tests</li></ul> <p>Presented by: Bruce Fireman, MA - Kaiser Permanente</p>



[Register Here](#)





# Job Opportunity

## Clinical Data Scientist

This position is with [Research IT](#), which is part of [Technology and Digital Solutions, Stanford Health Care](#). Please contact Priya Desai [prd@stanford.edu](mailto:prd@stanford.edu) if interested.

### Job Description:

The Clinical Data scientist will partner with researchers and clinicians to enable effective and efficient use of data and resources available via Stanford's Clinical Data repository (STARR: <https://starr.stanford.edu/about-starr> ) including the Electronic Medical Records in the OMOP common data format (<https://med.stanford.edu/starr-omop.html> ), Radiology imaging data and associated metadata, and new data types as they get integrated along with their databases and respective cohort query tools and interfaces (eg ATLAS: <https://www.ohdsi.org/atlas-a-unified-interface-for-the-ohdsi-tools/>, Montage: <https://www.nuance.com/healthcare/diagnostics-solutions/radiology-performance-analytics/mpower-clinical-analytics.html> ). This individual will help researchers and clinical staff maximize their understanding, interpretation and use of these clinical and research tools for more informed and productive research, clinical trials, patient care and quality outcome projects.

**Contact Priya Desai ([prd@stanford.edu](mailto:prd@stanford.edu)) for more information**





# Collaborator Showcase Abstracts Due FRIDAY

We are **3 DAYS AWAY** from the **June 18 deadline** for submissions for the 2021 Collaborator Showcase.

We are accepting submissions for posters, oral presentations and software demos.

[Home](#) > 2021 OHDSI Collaborator Showcase

## 2021 OHDSI Collaborator Showcase

Thank you for your interest in the 2021 OHDSI Collaborators Showcase! We are delighted that you are considering joining our research community and presenting your work at this year's virtual symposium showcase.

OHDSI's mission is to improve health by empowering a community to collaboratively generate evidence that promotes better health decisions and better care. We envision a world in which observational research produces a comprehensive understanding of health and disease. To achieve this goal, OHDSI has formed a multi-stakeholder, interdisciplinary collaboration that aims to bring out the value of health data through large-scale analytics and open-source software tools. OHDSI has established a global community of observational health researchers and a research network covering over 600 million patients.

OHDSI's achievements to date would not be possible if not for the hard work of our growing community members. Our annual Collaborator Showcase provides our community the opportunity to share their tremendous work. Last year, the OHDSI community produced more than 100 posters/talks/demos for our Collaborator Showcase.

Once again, we are inviting collaborators to participate in the Collaborator Showcase for this year's 2021 Global OHDSI Symposium. Collaborators will have the opportunity to submit their work for poster presentations, oral talks, and software demonstrations.

### Topics of Interest include:

- Observational data standards and management
- Methodological research
- Open-source analytics development
- Clinical research from OHDSI's analytic use cases:
  - Clinical characterization
  - Population-level estimation
  - Patient-level prediction

[Go to top](#)

### SHOWCASE STRUCTURE:

The showcase will be structured to highlight posters, oral talks, and software demonstrations.

We are currently working out all the details for the 2021 Global Symposium. Please continue to join our community calls (Tuesdays, 11 am ET), check the forums, MSTeams and the OHDSI website, as well as emails from OHDSI Events manager, to learn more details about an informative and productive showcase this year!



# Collaborator Showcase Abstracts Due FRIDAY



# OHDSI

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

- Who We Are ▾
- OHDSI Updates & News ▾
- Standards
- Software Tools
- OHDSI Studies
- Book of OHDSI ▾
- Resources ▾
- New To OHDSI? ▾
- EHDEN Academy ▾
- This Week In OHDSI ▾
- 2021 Global Symposium ▾
- Events/Collaborations ▾
- Collaborate in MSTeams ▾
- Follow OHDSI ▾

Information Home Page

Register (Free & Open To All)

2021 Collaborator Showcase Info



## Welcome to OHDSI!

The Observational Health Data Sciences and Informatics (or OHDSI, pronounced "Odyssey") program is a multi-stakeholder, interdisciplinary collaborative to bring out the value of health data through large-scale analytics. All our solutions are open-source.

## 2020 OHDSI Symposium

Our 2020 OHDSI Global Symposium brought together a global research community for 18 hours of open science, international collaboration and community fun. The day included research presentations from community members, panels that brought together leaders



A submission template can be found here: [Submission Template](#)

Each presenting author should upload their document as a PDF. The submission should meet the following guidelines:

- By submitting your work, the presenting author agrees to present at the OHDSI Symposium if their work is selected. Your document should be saved as a PDF using the following naming convention, where the "firstname" and "lastname" correspond to the name of the presenting author, and "title" should include keywords that summarize the title: `firstname-lastname_title_2021symposium`

[Go to top](#)

All submissions are due no later than 8pm (EST) on Friday, June 18, 2021.

All submissions will be peer-reviewed by the OHDSI Scientific Review Committee between **June 18-July 26**.

If you have been selected to present your work for the 2021 Symposium Collaborators Showcase, you will be notified via email by **Monday, August 2, 2021**.

Should you need additional assistance, please email us at [symposium@ohdsi.org](mailto:symposium@ohdsi.org).

To submit your research for the 2021 Collaborators Showcase, please click the link below and fill out the form (in order to access the submission form, you need to have a Google Account. If you need to set up a Google Account, please click here: [Create a Google Account](#))

[Submission Link](#)

## Background

This template should be used as a starting point for the submission. It should be a background of your understanding of the current state of the literature / science as it relates to the topic you are spotlighting in this brief report. This report should be on something that is unpublished in the literature. If you have a preprint on the topic and it is still not accepted in a peer-reviewed publication, we welcome the content for submission as well. Make sure to include a few citations in here of other people's work. This sentence has two reference citations.<sup>1,2</sup>

## Methods

This section should talk about the methods supporting your brief submission. Methods can be interpreted as both statistical methods. It can also be the reproducible, repeatable process you followed to generate the brief report content you are writing about.

## Results

More text of an additional paragraph, with a figure reference (Figure 1) and a figure inside a Word text box below. Figures need to be placed as close to the corresponding text as possible and not extend beyond one page. Use a minimum of 9pt font for Figure captions. You can include up to 3 figures in your submission (these are optional though highly encouraged).



This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting. This is additional text added just to show the one-column formatting.

2021 OHDSI Collaborators Showcase  
Brief Report Submission Form- Posters,  
Oral Talks and Software Demonstrations

Thank you for your interest in the 2021 OHDSI Collaborators Showcase! We are delighted that you are interested in showcasing your work at this year's virtual symposium showcase. For planning purposes, please take a few minutes to fill out this submission form to help the Scientific Review Committee better understand your solution.

By filling out this form you may choose if you would like to present your work as a poster, an oral talk or a software demonstration (or all three). If a poster or software demo, you will present it during the Collaborator Showcase at the symposium. If an Oral talk, you will present an estimated 7-minute talk at the symposium.

If you wish to present as a poster or an oral talk only, after you complete that question below the form will skip you to the section to upload your brief report. If you wish to present as a software demo only or also with a poster and/or oral talk, after you answer that question below, you will complete several questions on the software demo. You will then be asked to submit a one-page overview of your software. If you want to submit for all three (software demo, poster and/or talk), it will then ask you to submit a brief report for the poster and/or oral submission.

Although we strive to accommodate your requested presentation format, it is not guaranteed. If the review committee has selected your work to be presented at this year's showcase, you will be notified via email by August 2, 2021 and the presentation format will be confirmed at that time.

Topics should align with at least one of OHDSI's strategic areas of focus:

- Observational data standards and management
- Open-source analytics development
- Methodological research
- Clinical applications

## SUBMISSION INSTRUCTIONS

A brief report submission template can be found by using the below link  
[https://docs.google.com/document/d/1GADPitvH1eXHX\\_W9qBQIq-nv2gAVnloH2c7kCotWGak/edit?usp=sharing](https://docs.google.com/document/d/1GADPitvH1eXHX_W9qBQIq-nv2gAVnloH2c7kCotWGak/edit?usp=sharing)

The document can be downloaded as a Microsoft Word document by clicking on the link and selecting File->Download As...-> Microsoft Word (.docx).



## #JoinTheJourney





# Where Are We Going?

**Any other announcements  
of upcoming work, events,  
deadlines, etc?**





# Three Stages of The Journey

**Where Have We Been?**

**Where Are We Now?**

**Where Are We Going?**







# June 15: Professional Development Breakouts

## Clinical Epidemiology

Moderators: Talita Duarte-Salles and Dani Prieto-Alhambra



## Information/ Data Management

Moderators: Maxim Moinat and Mui Van Zandt



## Open-Source Software Development

Moderators: Greg Klebanov and Kees van Bochove



## Statistical Methods

Moderators: Yong Chen and Marc Suchard

